Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935303 | 0.84 | RAB9A (0.53) | KDM4EALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL4940513 | 0.81 | ALDH1A1 (0.56) | KDM4EALDH1A1MAPTNR4A1NPC1 | |
| SCHEMBL1630414 | 0.77 | KDM4E (0.51) | KDM4EALDH1A1MAPTNR4A1NPC1 | |
| SCHEMBL4420812 | 0.73 | EPHX2 (0.79) | KDM4EALDH1A1MAPTNR4A1NPC1 | |
| SCHEMBL4941283 | 0.73 | HSP90AA1 (0.41) | KDM4EALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL4939682 | 0.72 | ESR1 (0.48) | KDM4EALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4938798 | 0.71 | MAOA (0.39) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4939706 | 0.70 | HSP90AA1 (0.41) | MAPTNPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL12722777 | 0.69 | ALDH1A1 (0.55) | KDM4EALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4940666 | 0.69 | MAPT (0.43) | ALDH1A1MAPTNPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182857-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | claimed |
| EP-1853570-A2 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | Merck Patent GmbH (DE) | 2007-11-14 | — | — | EP | claimed |
| WO-2006087077-A2 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2006-08-24 | — | — | WO | claimed |
| US-8618285-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-1853570-B1 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20080182857-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
| EP-1853570-A2 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | Merck Patent GmbH (DE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087077-A2 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182857-A1 | Triazole Derivatives | HSP90AB1, HSP90AA1, HSP90B1 | KDM4E 3777/4885ALDH1A1 1580/4885MAPT 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.